AbbVie Announces Collaboration with Calico to Develop New R&D Facility
AbbVie and Calico announce a novel collaboration to accelerate the discovery, development, and commercialization of new therapies.
AbbVie and Calico, the Google-backed life sciences company, announced on Sept. 3, 2014 a novel R&D collaboration intended to help the two companies discover, develop, and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer.
Under the agreement, the companies will combine their complementary strengths to accelerate the availability of new therapies for age-related diseases. Calico will use its scientific expertise to establish a world-class R&D facility, with a focus on drug discovery and early drug development based in the San Francisco Bay Area. AbbVie will provide scientific and clinical development support and its commercial expertise to bring new discoveries to market.
Source: AbbVie
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
